Silibinin Exerts Anti-Cancer Activity on Human Ovarian Cancer Cells by Increasing Apoptosis and Inhibiting Epithelial-Mesenchymal Transition (Emt) Publisher Pubmed



Maleki N¹ ; Yavari N² ; Ebrahimi M³ ; Faisal Faiz A⁴ ; Khosh Ravesh R⁵ ; Sharbati A⁶ ; Panji M⁷ ; Lorian K⁸ ; Gravand A⁹ ; Abbasi M^{10, 11} ; Abazari O¹² ; Shafiee Mehr M¹³ ; Eskandari Y¹⁰ Show Affiliations
Source: Gene Published:2022

Abstract

Background: Silibinin, the principal flavonoid derived from milk thistle seeds, has been demonstrated to have strong inhibitory effects against human malignancies. The inhibitory function of silibinin on ovarian cancer, however, is not fully identified. In this essay, both in vivo and in vitro investigations were conducted to survey the silibinin's blocking effects on ovarian cancer. Methods: The impacts of silibinin on two ovarian cancer cell lines, SKOV-3 and A2870, were determined by evaluating cell viability, migration, invasion, and apoptosis. Q-RT-PCR and western blotting techniques were carried out to explore the protein levels of signaling pathway markers. A mouse xenograft model was utilized to determine the silibinin efficacy in inhibiting tumor growth. Results: After cell treatment with silibinin, cell viability, migration, and invasion were appreciably inhibited in cancer cell lines, but cell apoptosis was promoted. Also, silibinin reversed the epithelial-mesenchymal transition (EMT) mechanism by inducing E-cadherin expression and reducing N-cadherin and vimentin expression, suppressing the levels of regulators related to EMT such as Snail, Slug, and ZEB1 transcription factors, and also decreasing PI3K/AKT, Smad2/3, and β-catenin intermediate molecules in vitro. Silibinin effectively ameliorated tumor growth in vivo. Conclusion: silibinin could be considered a potent agent against ovarian cancer based on the results. © 2022